Pfizer reports positive top-line results from Phase 3 pain study of ALO-02
Study ALO-02-10-3001 included adult patients with moderate-to-severe chronic non-cancer pain lasting at least three months and requiring a continuous around-the-clock opioid analgesic for an extended period of time.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.